bumetanide (bumex) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Bumetanide is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. It blocks the reabsorption of sodium and fluid from the kidney's tubules. The most frequent clinical adverse reactions considered probably or possibly related to bumetanide are muscle cramps (seen in 1.1% of treated patients), dizziness (1.1%), hypotension (0.8%), headache (0.6%), nausea (0.6%) and encephalopathy (in patients with preexisting liver disease) (0.6%). One or more of these adverse reactions have been reported in approximately 4.1% of patients treated with Bumex (bumetanide). Lithium should generally not be given with diuretics (such as Bumex (bumetanide)) because they reduce its renal clearance and add a high risk of lithium toxicity. Bumex (bumetanide) may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.   NCATS

Chemistry

  • SMILES: CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
  • InChIKey: MAEIEVLCKWDQJH-UHFFFAOYSA-N
  • Mol. Mass: 364.416
  • ALogP: 3.04
  • ChEMBL Molecule:
    bumetanide  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0640 - $2.4090
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid | 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid | 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid | 3-butylamino-4-phenoxy-5-sulfamoylbenzoic acid | betinex | bufenox | bumetanida | bumetanide | bumetanidum | bumethanide | bumex | burinex | lixil | ro-106338

Organizations (55)

Research & Development (41)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (5)


 

Edema (approved 1983)

Heart Failure

Hypertension

Kidney Diseases

Nephrotic Syndrome

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Autism Spectrum Disorder (Phase 3)

Autistic Disorder (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 1)

Heart Failure ()

Heart Failure, Diastolic (Phase 4)

Hypokalemic Periodic Paralysis (Phase 2)

Parkinson Disease (Phase 2)

Renal Insufficiency, Chronic (Phase 4)

Seizures (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial Organizations: 41

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue